Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
The U.S. Food and Drug Administration is speeding up its review of new drugs, yet often fails to keep track of safety issues with those medicines once they reach patients, according to government investigators.Last year the agency approved 45 first-of-a-kind drugs – the highest number in 19 years – with most reviewed in approximately eight months.The Department of Health and Human Services, which oversees the FDA, said the agency is conducting internal evaluations to improve its computerized tracking system, which it acknowledged is challenging to update.The FDA currently has four systems for expediting drug reviews.
FOLLOW THIS ARTICLE